Investors are always looking for stocks that are poised to beat at earnings season and Pacira Pharmaceuticals, Inc.
In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 12 cents per share for PCRX, compared to a broader Zacks Consensus Estimate of a loss of 15 cents per share.
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market.
In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon.
Click to see the stocks right now >> Want the latest recommendations from Zacks Investment Research?